The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer - A phase II study

被引：5

作者：

Michels, J.

Geldart, T.

Darby, A.

Craddock, L.

Iveson, A.

Richardson, L.

Iveson, T.

机构：

[1] Southampton Gen Hosp, Oncol Unit, Southampton SO9 4XY, Hants, England

[2] Salisbury Dist Hosp, Oncol Unit, Salisbury, Wilts, England

来源：

CLINICAL ONCOLOGY | 2006年 / 18卷 / 06期

关键词：

advanced colorectal cancer; mitomycin-C; raltitrexed;

D O I：

10.1016/j.clon.2006.01.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aims: To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer. Materials and methods: A phase II study. Results: In total, 22 patients were treated with a combination of raltitrexed 3 mg/m(2) every 3 weeks and mitomycin-C 7 mg/m(2) every 6 weeks for up to 24 weeks. The study was closed early for safety reasons as there were three unexpected treatment-related deaths. The overall response rate was 20%, and a further 40% achieved stable disease. The median time to progression was 3.9 months and the median overall survival time was 11.6 months. Conclusion: Owing to the potential for increased toxicity, the combination of raltitrexed and mitomycin-C cannot be recommended as first-line treatment in patients with advanced colorectal cancer.

引用

页码：431 / 435

页数：5

共 50 条

[31] COMBINATION CHEMOTHERAPY OF ADVANCED COLORECTAL-CANCER WITH 5-FLUOROURACIL, CARMUSTINE, AND MITOMYCIN-C
HEIM, ME
ROMER, W
EDLER, L
QUEISSER, W
TUMORDIAGNOSTIK & THERAPIE, 1983, 4 (03) : 122 - 125
[32] COMBINATION OF DACARBAZINE, MITOMYCIN-C, 5-FLUOROURACIL AND VINCRISTINE IN ADVANCED COLORECTAL-CANCER
FALKSON, G
PRETORIUS, HL
FALKSON, HC
SCHOEMAN, HS
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1983, 11 (03) : 203 - 204
[33] A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma
Rougier, P
Ducreux, M
Kerr, D
Carr, BI
Francois, E
Adenis, A
Seymour, L
ANNALS OF ONCOLOGY, 1997, 8 (05) : 500 - 502
[34] Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
S Rao
D Cunningham
T Price
M E Hill
P J Ross
N Tebbutt
A R Norman
J Oates
P Shellito
British Journal of Cancer, 2004, 91 : 839 - 843
[35] PHASE-II STUDY OF HEXAMETHYLMELAMINE ALONE AND IN COMBINATION WITH MITOMYCIN-C AND VINCRISTINE IN ADVANCED BREAST-CARCINOMA
LEGHA, SS
BUZDAR, AU
HORTOBAGYI, GN
DISTEFANO, A
WISEMAN, CL
YAP, HY
BLUMENSCHEIN, GR
BODEY, GP
CANCER TREATMENT REPORTS, 1979, 63 (11-1): : 2053 - 2056
[36] Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
Rao, S
Cunningham, D
Price, T
Hill, ME
Ross, PJ
Tebbutt, N
Norman, AR
Oates, J
Shellito, P
BRITISH JOURNAL OF CANCER, 2004, 91 (05) : 839 - 843
[37] Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer:: a phase II study
Feliu, J
Salud, A
Escudero, P
Lòpez-Gómez, L
Pericay, C
Castañón, C
de Tejada, MRL
Rodríguez-García, JM
Martínez, MP
Martín, MS
Sánchez, JJ
Barón, MG
BRITISH JOURNAL OF CANCER, 2004, 90 (08) : 1502 - 1507
[38] TREATMENT OF ADVANCED CERVICAL-CANCER BY A COMBINATION OF PEPLOMYCIN, VINCRISTINE, MITOMYCIN-C, AND CISPLATIN
SUGIMORI, H
IWASAKA, T
FUKUDA, K
HAYASHI, Y
HACHISUGA, T
GYNECOLOGIC ONCOLOGY, 1989, 34 (02) : 180 - 182
[39] Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer:: A phase II study
Gambacorta, MA
Valentini, V
Morganti, AG
Mantini, G
Miccichè, F
Ratto, C
Di Miceli, D
Rotondi, F
Alfieri, S
Doglietto, GB
Vargas, JG
De Paoli, A
Rossi, C
Cellini, N
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : 130 - 138
[40] Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer
Zalcberg, J
ANTI-CANCER DRUGS, 1997, 8 : S17 - S22

← 1 2 3 4 5 →